Evercore Maintains Akero Therapeutics(AKRO.US) With Buy Rating, Maintains Target Price $38

Moomoo NewsDec 16, 2024 08:33 ET · Ratings

Possible Bearish Signals With Akero Therapeutics Insiders Disposing Stock

Simply Wall StDec 15, 2024 07:18 ET

Insider Sale: Senior VP of $AKRO (AKRO) Sells 925 Shares

Quiver QuantitativeDec 12, 2024 20:31 ET

Akero Therapeutics to Present at the 7th Annual Evercore ISI HealthCONx Conference

Akero TherapeuticsNov 26, 2024 00:00 ET

Akero Therapeutics Receives Buy Rating for Promising Efruxifermin Developments in MASH Treatment

TipRanksNov 22, 2024 06:25 ET · Ratings

Akero a New Buy at Citi on Liver Disease Asset

Seeking AlphaNov 18, 2024 12:33 ET